Novo Nordisk A/S, the drugmaker behind the hit obesity treatment Wegovy, signed research deals with a pair of biotechs backed by Flagship Pioneering, agreeing to pay as much as $1.1 billion to develop new technologies to tackle diseases linked to weight.
The first project, with Omega Therapeutics Inc., aims to use the body’s mechanisms for controlling how genes work to treat obesity by boosting metabolism, instead of reducing the appetite. The second, with Cellarity Inc., will target a drug for an obesity-related liver disease called metabolic dysfunction-associated steatohepatitis, or MASH.
Both projects are early ...
